Payment overview · 2025
General Payments
$85.72
4 reported records · 3 companies
Healthcare provider profile · identity verified
Michael Lawson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KEARNEY, NE · NPI 1205819455
Verified facts
What the public records show
CMS Open Payments records show Michael Lawson, M.D. received $85.72 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.31 | 50.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.66 | 29.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.75 | 19.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.72 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 43 |
| Metformin Hcl | Metformin Hcl | 215 | 48 |
| Potassium Chloride | Potassium Chloride | 215 | 38 |
| Lisinopril | Lisinopril | 212 | 47 |
| Omeprazole | Omeprazole | 204 | 37 |
| Furosemide | Furosemide | 176 | 24 |
| Allopurinol | Allopurinol | 172 | 33 |
| Losartan Potassium | Losartan Potassium | 172 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 31 |
| Gabapentin | Gabapentin | 153 | 30 |
| Tramadol Hcl | Tramadol Hcl | 151 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 23 |
| Simvastatin | Simvastatin | 139 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 16 |
| Irbesartan | Irbesartan | 107 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 15 |
| Glimepiride | Glimepiride | 104 | 16 |
| Eliquis | Apixaban | 99 | 14 |
| Ozempic | Semaglutide | 99 | 14 |
| Memantine Hcl | Memantine Hcl | 96 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 82 | suppressed |
| Meloxicam | Meloxicam | 81 | 22 |
| Celecoxib | Celecoxib | 77 | 11 |
| Warfarin Sodium | Warfarin Sodium | 76 | 14 |
| Buspirone Hcl | Buspirone Hcl | 73 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 23 |
| Carvedilol | Carvedilol | 67 | 17 |
| Famotidine | Famotidine | 67 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Spironolactone | Spironolactone | 65 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 63 | 15 |
| Montelukast Sodium | Montelukast Sodium | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 56 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 55 | 11 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 27 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Prednisone | Prednisone | 46 | 25 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Bumetanide | Bumetanide | 45 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Nystatin | Nystatin | 29 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Levofloxacin | Levofloxacin | 27 | 23 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 24 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 15 |
| Azithromycin | Azithromycin | 22 | 21 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Torsemide | Torsemide | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lunesta | Eszopiclone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.72 · 4 records | PFIZER INC. | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, PREVNAR 20, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error